Merck & Co Inc (XBUL:6MK)
лв 97.9 0 (0%) Market Cap: 475.39 Bil Enterprise Value: 520.01 Bil PE Ratio: 20.83 PB Ratio: 5.65 GF Score: 87/100

Merck & Co Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 09, 2022 / 07:30PM GMT
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

Okay. Great. Well, thanks, everybody, for joining us. Good afternoon. This is going to be a 25-minute discussion with Merck's EVP and President of MRL, or Merck Research Laboratories, Dr. Dean Li. I'm Seamus Fernandez, one of the biopharma team senior therapeutics analysts here at Guggenheim, and I'm really pleased to have Dr. Li join us as part of our fourth annual oncology conference. Unfortunately, still virtual, but I'm confident that when we do this again next year, we're going to be doing this in person. Boy, I hope that -- I'm touching wood as we speak. So hopefully, we'll be in the right place.

Questions & Answers

Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

So while Dr. Li leads the company's worldwide human vaccines and therapeutics research development organization, in the spirit of today's discussion and focus, we are going to focus on oncology, in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot